#4

IN THE UNITED STATES PATENT AND TRADEMARK PECEIVED

In re Application of

Emil Israel KATZ

MAR 0 4 2002

Serial No.

09/982,172

TECH CENTER 1600/2900

Filed For:

LEB 5 8 SOLL STATE

October 19, 2001

PEPTIDES REPRESENTATIVE OF

POLYPEPTIDES OF INTEREST ...

Attorney Docket

01/22283

Art Unit

:

Commissioner of Patents and Trademarks Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein

Attorney for Applicant Registration No. 25,457

February 26, 2002

Please type a plus sign (+) inside this box — FEB 2 8 2000

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031 atent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required be spond to a collection of information unless it contains a valid OMB control number

Initials		NFOR TATE (use	as many Int Docume Kind Co (if know	ON DISC F BY API sheets as need of Unit ode² Na Comis	i.s. PATENT ame of Patentee of Cited Doo et al	DOCUMENTS or Applicant	Date of Publication of Cited Document MM-DD-YYYY	09/982,172 October 19, 20 KATZ et al 01/22283 Pages, columns, 1 Where Releval Passages or Rele Figures Appea	
Examiners Initials	Cite No. 1	U.S. Pate Number	as many Int Docume Kind Co (if know	of of unt ode² Na Comis	eessary) S.S. PATENT ame of Patentee of Cited Doo et al	DOCUMENTS or Applicant	Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number Date of Publication of Cited Document MM-DD-YYYY	October 19, 20 KATZ et al 01/22283 Pages, columns, I Where Releva Passages or Rele	
Examiners Initials	Cite No. 1	U.S. Pate Number	as many Int Docume Kind Co (if know	of of unt ode² Na Comis	eessary) S.S. PATENT ame of Patentee of Cited Doo et al	DOCUMENTS or Applicant	First Named Inventor Group Art Unit Examiner Name Attorney Docket Number Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, Where Releva	
Examiners Initials	Cite No. 1	U.S. Pate Number	as many 1 Int Docume Kind Co (if know)	sheets as ned of Unit ode² vn) Na Comis	(.S. PATENT The me of Patentee of Cited Door et al	or Applicant	Group Art Unit Examiner Name Attorney Docket Number Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, I Where Releva Passages or Rele	
Examiners Initials	No. 1	U.S. Pate Number	nt Docume Kind Co (if know	of Unit Ode ² Na Comis	i.s. PATENT ame of Patentee of Cited Doo et al	or Applicant	Examiner Name Attorney Docket Number Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, I Where Releva Passages or Rele	
Examiners Initials	No. 1	Number 6,261	Kind Co (if know	nt Ode² Na	ame of Patentee of Cited Doo et al	or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, I Where Releva Passages or Rele	
Initials	No. 1	Number 6,261	Kind Co (if knov	ode ² Na Comis	ame of Patentee of Cited Doo et al	or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Where Releval Passages or Rele	
Initials	No. 1	Number 6,261	Kind Co (if knov	ode² Na Comis	of Cited Doo		Cited Document MM-DD-YYYY	Where Releva Passages or Rele	
Initials	No. 1	6,261	(if knov	Comis	of Cited Doo		Cited Document MM-DD-YYYY	Where Releva Passages or Rele	
								Where Releva Passages or Rele	
	AB	5,872	2,234	Bandn	an et al		07-17-2001		
					Bandman et al		02-16-1999		
					.			 	
	-+	-							
	-+			.				 	
	+		_					1	
			_					 	
			1						
					-		-		
		·			EIGN PATE	NT DOCUMEN	TS		
	Cite No. ¹	Office ³	gn Patent I	Kind Code ⁵ (if known)		of Patentee or of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	
	\rightarrow			 					
	+			-		<u> </u>	·		
				 					
	\dashv			-			-		
				 	 			-	
Examiner Signature	<u>_</u>			<u> </u>	<u> </u>		Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this by TRADEMA

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no per uired to respond to a collection of information unless it contains a valid OMB control number

•	٥.			Complete if Known						
	5ા	ubstitute for form 1449A/PTO	Applica	Application Number 09/9						
	INF	ORMATION DISCLOSURE	Filing I			ber 19, 200				
i	STA	amed Inventor	KATZ et al							
	SIF	Art Unit								
		(use as many sheets as necessary)	Examir	ner Name						
Sheet		2 of	Attorney Docket Number 01/2		01/22	2283				
		OTHER PRIOR ART – NON PATENT LITER	ATURE	DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
	BA									
	BB	Söderlind et al, "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination", <i>Immunotechnology</i> , 4:279-285, 1999								
	ВС	Söderlind et al, "Recombining Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries", <i>Nature Biotechnology</i> , 18:852-856, 2000								
	BD	Ohlin et al, Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition", <i>Molecular Immunology</i> , 33(1):47-56, 1996								
	BE	Hemminki et al, "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs", <i>Immunotechnology</i> , 4:59-69, 1998								
	BF	Barbas III et al, "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site", <i>Proc. Natl. Acad. Sci. USA</i> , 88:7978-7982, 1991								
	BG	Hoogenboom et al, "Antibody Phage Display Technology and its Applications", Molecular Immunology, 4:1-20, 1998								
	ВН	Haupt et al, "Plastic Antibodies: Developments and Applications", <i>Trends Biotech.</i> , 16:468-476, 1998								
	BI	Vlatakis et al, "Drug Assay Using Antibody Mimics M Nature, 361:645647, 1993	ade by N	Aolecular Imprin	ting",					
	BJ	Arnon, R., "Synthetic Peptides as the Basis for Vaccine Immunology, no further info given	Design'	", Molecular						
	BK	Arnheiter et al, "Physicochemical and Antigenic Prope Human Leukocyte Interferon" <i>Nature</i> , 294:278-280, 19	981							
	BL	Mariani et al, "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein", <i>Molecular Immunology</i> , 24(3):297-303, 1987								
	ВМ	Chames et al, "Antibody Engineering and its Applications in Tumor Targeting and Intracellular Immunization", FEMS Microbiology Letters, 189:1-8, 2000								
	BN .	Hoogenboom et al, "Natural and Designer Binding Sites Made by Phage Display Technology", <i>Immunology Today</i> , 21(8):371-378, 2000								
	ВО	Nelson et al, "Demystified Monoclonal Antibodies", J. Clin. Pathol.: Mol Pathol., 53:111-117, 2000								
	BP	Li, Min, "Applications of Display Technology in Protein Analysis", Nature Biotechnology, 18:1251-1256, 2000								
	BQ									
Examiner Signature				Date Considered						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.